Article: SMITHKLINE BEECHAM'S AUGMENTIN(R) CLEARED IN U.S. IN MORE CONVENIENT DOSING REGIMEN FOR CHILDREN

Twice-A-Day Regimen and New Formulations Reduce the Most Troublesome

Side Effect of Drug Widely Used in Fight Against Resistant Bacteria

 
 New Fruit Flavors, Too 

PHILADELPHIA, June 3 /PRNewswire/ -- SmithKline Beecham (SB) (NYSE: SBH) announced today that it has received U.S. marketing clearance for a more convenient pediatric dosing regimen of Augmentin amoxicillin/clavulanate potassium), one of the most frequently used antibiotics for infections involving drug-resistant bacteria. Also cleared were new pediatric formulations in new dosage strengths.

The new, twice-daily (BID) pediatric dosing schedule provides the same ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!